Boston Scientific Corp.

With the Edwards Intuity Elite valve system, Edwards Lifesciences aims to offer a minimally invasive therapy to complex aortic stenosis patients.

In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.

On June 6, 2017, Medtronic (MDT) received the Health Canada license for its SureTune3 software for DBS (deep brain stimulation) therapy.

Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets.

The US medical device industry is a global leader. Its market was valued at ~$140 billion for 2016. It represents ~45% of the global market.

Dentsply Sirona’s Technology segment sales Dentsply Sirona (XRAY) reported ~$900 million of revenues worldwide in 1Q17. Of that, ~$389 million was generated through Dentsply Sirona’s Technology segment, which contributed ~43.2% to Dentsply Sirona’s total revenues. On a constant currency basis, the Technology segment’s sales declined by approximately 8.1%. The segment’s sales were flat in Europe. The […]

Becton, Dickinson and Company (BDX) generates ~$1 billion from its Infection Prevention business.

Edwards Lifesciences (EW) has a robust product pipeline in its THV (transcatheter heart valve) segment, with Sapien 3 as the segment’s leading product.

Of Medtronic’s ~$7.3 billion in worldwide revenue in fiscal 2Q17, ~$1.8 billion came from its RTG segment, representing ~25% of the company total.

On September 27, 2016, Boston Scientific (BSX) announced the acquisition of EndoChoice Holdings for $210 million.

In 2Q16, Dentsply Sirona’s leading position in the Digital Sensor category and rebound in the Lab business drove its Technologies segment sales.

Varian Medical Systems (VAR) had gross orders value of $310 million in 2015.

Medtronic plans to launch more than 80 products over the next three years.

Medtronic’s (MDT) Restorative Therapies Group (or RTG) segment, formed around seven years ago, has a strong market position today.

C. R. Bard’s (BCR) Oncology segment contributes around 27% of the total revenues of the company.

Intuitive Surgical aims to include a larger patient population under its MIS treatments and to provide better surgery outcomes and lower recovery times.

Boston Scientific has strategically expanded in these geographies through organic as well as inorganic strategies.

Boston Scientific registered emerging market sales growth of approximately 13% in 2015, representing a steady growth in international markets.

Boston Scientific’s (BSX) MedSurg segment contributes around 33% to the company’s total revenues and is the company’s second-largest segment.

Boston Scientific’s (BSX) Cardiovascular segment consists of minimally invasive technologies to treat patients with a wide range of heart and vascular diseases. It is BSX’s largest business segment and generated ~39% of the company’s total revenues in 2015.

Starting in 2011, Boston Scientific (BSX) has undertaken cost-cutting programs and reorganization efforts to turn the company’s battered financials around. In 2014, BSX started registering positive growth and profitability.

The Fidelity Magellan Fund (FMAGX) invests primarily in common stocks of US and foreign issuers. It invests in either growth stocks, value stocks, or both.

Abbott’s Established Pharmaceuticals segment is a consumer-oriented segment with a consumer mix of around 75% self-pay consumers and 25% third-party payers.

Becton, Dickinson and Company is one of the five biggest medical device companies in the United States.

Abbott Laboratories is one of the leading companies in the diagnostic products space in the United States, with sales of around $4.7 billion in 2014.

Abbott Laboratories operates across more than 150 countries, employs over 73,000 people, and is the global leader in the nutrition subsector.

Traditionally, the United States has been home to the most advanced technological inventions in the medical device industry.

Medical device companies are driven by innovation and inventions that involve high research and development (or R&D) costs.

Medical devices are classified as per the level of control required by the Food, Drug, and Cosmetic Act (or FD&C Act).

The US medical device industry has rebounded sharply since its 2008 decline, and it is trading at a high PE of 21.9x.

Venture capital is one of the major sources of capital for the US medical device industry.

To extend cost-effective, high-quality medical devices and therapies, Medtronic aims to organize its marketing and sales teams around physician preferences.

Medtronic’s Restorative Therapies Group’s net sales in fiscal 2015 reached ~$6.8 billion, which represents an increase of 4% over the prior fiscal year.

Medtronic generates revenue through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies, Restorative Therapies, and the Diabetes Group.

Headquartered in Minnesota, Medtronic is the world’s largest pure-play medical device company, with operations in 160 countries and over 85,000 employees.

Looking at the US economy for the last three years might help us understand which phase of the business cycle the US economy is in right now.

The Medical Devices and Diagnostics segment contributes over 37% of Johnson & Johnson’s revenue. In 2014, the segment generated about $27.5 billion in revenue.